Highlight publications
Craddock, C, Jackson, A, Loke, J, Siddique, S, Hodgkinson, A, Mason, J, Andrew, G, Nagra, S, Malladi, R, Peniket, A, Gilleece, M, Salim, R, Tholouli, E, Potter, V, Crawley, C, Wheatley, K, Protheroe, R, Vyas, P, Hunter, A, Parker, A, Wilson, K, Pavlu, J, Byrne, J, Dillon, R, Khan, N, Mccarthy, N & Freeman, SD 2020, 'Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.20.02308
Freeman, S & Craddock, C 2020, 'Less is not necessarily more: toward a rational selection of the conditioning regimen in acute myeloid leukemia', Journal of Clinical Oncology , vol. 38, no. 12, pp. 1249-1251. https://doi.org/10.1200/JCO.19.03161
Freeman, S, Hills, R, Virgo, P, Khan, N, Couzens, S, Dillon, R, Gilkes, A, Upton, L, Nielsen, OJ, Cavenagh, JD, Jones, G, Khwaja, A, Cahalin, P, Thomas, I, Grimwade, D, Burnett, AK & Russell, NH 2018, 'Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations', Journal of Clinical Oncology , vol. 36, no. 15, pp. 1486-1497. https://doi.org/10.1200/JCO.2017.76.3425
Short, NJ, Zhou, S, Fu, C, Berry, DA, Walter, RB, Freeman, SD, Hourigan, CS, Huang, X, Nogueras, GG, Hwang, H, Qi, X, Kantarjian, H & Ravandi, F 2020, 'Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.', JAMA Oncology, vol. 6, no. 12, pp. 1890-1899. https://doi.org/10.1001/jamaoncol.2020.4600
Schuurhuis, GJ, Heuser, M, Freeman, S, Béné, M-C, Buccisano, F, Cloos, J, Grimwade, D, Haferlach, T, Hills, RK, Hourigan, CS, Jorgensen, JL, Kern, W, Lacombe, F, Maurillo, L, Preudhomme, C, van der Reijden, BA, Thiede, C, Venditti, A, Vyas, P, Wood, BL, Walter, RB, Döhner, K, Roboz, GJ & Ossenkoppele, GJ 2018, 'Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party', Blood. https://doi.org/10.1182/blood-2017-09-801498
Recent publications
Article
Röhnert, MA, Kramer, M, Schadt, J, Ensel, P, Thiede, C, Krause, SW, Bücklein, V, Hoffmann, J, Jaramillo, S, Schlenk, RF, Röllig, C, Bornhäuser, M, McCarthy, N, Freeman, S, Oelschlägel, U & von Bonin, M 2022, 'Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia', Leukemia, vol. 36, no. 9, pp. 2208-2217. https://doi.org/10.1038/s41375-022-01647-5
Tettero, JM, Freeman, S, Buecklein, V, Venditti, A, Maurillo, L, Kern, W, Walter, RB, Wood, BL, Roumier, C, Philippé, J, Denys, B, Jorgensen, JL, Bene, MC, Lacombe, F, Plesa, A, Guzman, ML, Wierzbowska, A, Czyz, A, Ngai, LL, Schwarzer, A, Bachas, C, Cloos, J, Subklewe, M, Fuering-Buske, M & Buccisano, F 2022, 'Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European Leukemianet MRD Working Party', HemaSphere, vol. 6, no. 1, e676, pp. E676. https://doi.org/10.1097/HS9.0000000000000676
Tazi, Y, Arango-Ossa, JE, Zhou, Y, Bernard, E, Thomas, I, Gilkes, A, Freeman, S, Pradat, Y, Johnson, SJ, Hills, R, Dillon, R, Levine, MF, Leongamornlert, D, Butler, A, Ganser, A, Bullinger, L, Döhner, K, Ottmann, O, Adams, R, Döhner, H, Campbell, PJ, Burnett, AK, Dennis, M, Russell, NH, Devlin, SM, Huntly, BJP & Papaemmanuil, E 2022, 'Unified classification and risk-stratification in acute myeloid leukemia', Nature Communications, vol. 13, no. 1, 4622. https://doi.org/10.1038/s41467-022-32103-8
Heuser, M, Freeman, SD, Ossenkoppele, GJ, Buccisano, F, Hourigan, CS, Ngai, LL, Tettero, JM, Bachas, C, Baer, C, Béné, M-C, Bücklein, V, Czyz, A, Denys, B, Dillon, R, Feuring-Buske, M, Guzman, ML, Haferlach, T, Han, L, Herzig, JK, Jorgensen, JL, Kern, W, Konopleva, MY, Lacombe, F, Libura, M, Majchrzak, A, Maurillo, L, Ofran, Y, Philippe, J, Plesa, A, Preudhomme, C, Ravandi, F, Roumier, C, Subklewe, M, Thol, F, Loosdrecht, AAVD, Reijden, BAVD, Venditti, A, Wierzbowska, A, Valk, PJM, Wood, BL, Walter, RB, Thiede, C, Döhner, K, Roboz, GJ & Cloos, J 2021, '2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party', Blood, vol. 138, no. 26, pp. 2753–2767. https://doi.org/10.1182/blood.2021013626
Russell, NH, Hills, RK, Thomas, A, Thomas, I, Kjeldsen, L, Dennis, M, Craddock, C, Freeman, S, Clark, RE & Burnett, AK 2021, 'Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial', Haematologica, vol. 2021, 279010. https://doi.org/10.3324/haematol.2021.279010
Freeman, SD & Craddock, C 2021, 'Selection of conditioning intensity for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplasia - new evidence emerges', Transplantation and cellular therapy, vol. 27, no. 6, pp. 443-445. https://doi.org/10.1016/j.jtct.2021.05.010
Snel, AN, Kelder, A, Scholten, WJ, Khan, N, Metzner, M, Irno-Consalvo, M, Sugita, M, de Jong, A, Oude Alink, S, Eidhof, H, Wilhelm, M, Feuring-Buske, M, Slomp, J, van der Velden, VHJ, Sonneveld, E, Guzman, M, Roboz, GJ, Buccisano, F, Vyas, P, Freeman, S, Bachas, C, Ossenkoppele, GJ, Schuurhuis, GJ & Cloos, J 2020, 'Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting', British Journal of Haematology, vol. 190, no. 6, pp. 891-900. https://doi.org/10.1111/bjh.16594
Burnett, AK, Russell, NH, Hills, RK, Knapper, S, Freeman, S, Huntly, B, Clark, RE, Thomas, IF, Kjeldsen, L, McMullin, MF, Drummond, M, Kell, J & Spearing, R 2020, 'Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses', Journal of Clinical Oncology , pp. JCO2001170. https://doi.org/10.1200/JCO.20.01170
Dillon, R, Potter, N, Freeman, S & Russell, N 2020, 'How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).', British Journal of Haematology. https://doi.org/10.1111/bjh.17185
Dillon, R, Hills, RK, Freeman, SD, Potter, N, Jovanovic, J, Ivey, A, Kanda, AS, Runglall, M, Foot, N, Valganon, M, Khwaja, A, Cavenagh, J, Smith, ML, Ommen, HB, Overgaard, U, Dennis, M, Knapper, S, Kaur, H, Taussig, DC, Mehta, P, Raj, K, Novitzky-Basso, I, Nikolousis, E, Danby, RD, Krishnamurthy, P, Hill, K, Finnegan, D, Alimam, S, Hurst, E, Johnson, P, Khan, AB, Salim, R, Craddock, CF, Ruth Lilian Spearing, D, Gilkes, AF, Gale, RE, Alan Kenneth Burnett, Russell, NH & Grimwade, D 2020, 'Molecular MRD status and outcome after transplantation in NPM1-mutated AML', Blood, vol. 135, no. 9, pp. 680-688. https://doi.org/10.1182/blood.2019002959
Basheer, F, Giotopoulos, G, Meduri, E, Yun, H, Mazan, M, Sasca, D, Gallipoli, P, Marando, L, Gozdecka, M, Asby, R, Sheppard, O, Dudek, M, Bullinger, L, Döhner, H, Dillon, R, Freeman, S, Ottmann, O, Burnett, A, Russell, N, Papaemmanuil, E, Hills, R, Campbell, P, Vassiliou, GS & Huntly, BJP 2019, 'Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML', The Journal of Experimental Medicine, vol. 216, no. 4, pp. 966-981. https://doi.org/10.1084/jem.20181276
Chapter
Venditti, A, Valk, P, Russell, NH & Freeman, S 2021, Future developments: measurable residual disease. in C Röllig & GJ Ossenkoppele (eds), Acute Myeloid Leukemia. 1 edn, Chapter 18, Hematologic Malignancies, Springer, pp. 317-337. https://doi.org/10.1007/978-3-030-72676-8_18
Comment/debate
Craddock, C, Jackson, A & Freeman, SD 2021, 'Reply to G. Gui et al', Journal of Clinical Oncology, vol. 39, no. 21, pp. 2416-2417. https://doi.org/10.1200/JCO.21.00603
Editorial
Freeman, S 2022, 'Delving the depths of MRD negativity in acute myeloid leukemia', Haematologica. https://doi.org/10.3324/haematol.2022.280747
Freeman, SD & Valk, P 2022, 'Transplant in older adults with AML: genomic wheat and chaff', Blood, vol. 139, no. 24, pp. 3459-3461. https://doi.org/10.1182/blood.2022016195